Emerging markets are becoming increasingly important to biopharmaceutical companies. With their enormous patient populations, lower study costs, and favourable regulatory environments, it’s easy to see why interest in the area is increasing.
Kendle has a strong and growing presence in the world’s emerging markets. In 2009, we added to our already established clinical trial centers in China, Hong Kong, India, Korea, Singapore, Taiwan and Latin America, by opening a further three offices in the Philippines, Malaysia and Thailand. Our in-depth knowledge of local regulatory requirements and patient culture make us an invaluable partner when thinking about expanding your development program to these regions.